MPOXED

Mpox no longer an international health emergency, says WHO chief

September 5, 2025

The World Health Organization has declared that mpox no longer represents a Public Health Emergency of International Concern, marking a major milestone in the global response. Sustained declines in cases in the Democratic Republic of the Congo, Burundi, Sierra Leone, and Uganda informed this decision. While the announcement reflects clear progress, it should not be mistaken for eradication. Mpox continues to pose risks in vulnerable populations and under-resourced areas. The decision underscores the value of international cooperation and targeted interventions, while reminding the global community that vigilance, investment in surveillance, and equitable vaccine access remain essential to prevent resurgence.

Mpox Still a Continental Emergency, Africa CDC Advisory Group Recommends

September 4, 2025

The Africa CDC’s Emergency Consultative Group has recommended that the Public Health Emergency of Continental Security (PHECS) for mpox remain in place, despite recent declines in cases. While weekly confirmed infections fell by 52 percent between May and August 2025, new surges in Ghana, Liberia, Kenya, and Zambia highlight the fragility of progress. Infant deaths, case fatality rates above one percent in several countries, and gaps in testing and vaccine access underscore persistent risks. The Group warned that lifting the PHECS prematurely could weaken political will and resources. Sustained vigilance, expanded vaccination, and stronger surveillance remain essential to prevent resurgence.

Mpox Resurgence: A Global Wake-Up Call for Zoonotic Disease Preparedness

September 4, 2025

The resurgence of mpox highlights the fragility of global health security. Once primarily linked to zoonotic spillovers in Central and West Africa, the virus is now sustained through human-to-human transmission across more than 100 countries. A recent review underscores how waning smallpox immunity, ecological disruption, and inequitable vaccine access fuel its spread. Vulnerable groups—immunocompromised individuals, pregnant people, and children—remain at highest risk of severe outcomes. While tools like MVA-BN vaccines and antivirals exist, their uneven distribution threatens to entrench mpox. The lesson is clear: without equity, sustained investment, and One Health approaches, regional outbreaks will continue to spark global crises.

Two Years On: MVA-BN Vaccine Still Shields Against Severe Mpox, But Equity and Boosters Loom as Next Frontiers

September 3, 2025

A new study in The Lancet Primary Care offers the strongest evidence yet that the MVA-BN vaccine provides durable protection against severe mpox more than 18 months after vaccination. Australian researchers found full vaccination reduced hospitalization risk by 89 percent, despite antibody levels waning within months. Breakthrough infections were milder, underscoring the vaccine’s continued clinical value. The absence of outcome data for HIV-positive individuals remains a critical gap, especially as outbreaks intensify in high-prevalence regions. Policymakers now face key questions: whether booster doses are needed, how to prioritize high-risk populations, and how to ensure global equity in vaccine access.

Mpox still present in Virginia, as VDH tracks multiple cases in the commonwealth

September 3, 2025

Mpox, first detected in Virginia during the 2022 outbreak, continues to persist even as case numbers remain lower than in the initial surge. The Virginia Department of Health reports 23 cases so far in 2025, nearly matching the total for all of 2024. Transmission occurs primarily through close or sexual contact, with rashes serving as the most identifiable symptom. Men account for 95 percent of cases, and individuals with HIV or other immunocompromising conditions are most vulnerable to severe outcomes. Public health officials stress vaccination, especially for those with multiple partners, to reduce risk and protect communities across the commonwealth.

Three powerful antibodies discovered with potential to treat mpox

September 3, 2025

Researchers at Mount Sinai have identified three monoclonal antibodies that block mpox viral spread and prevent severe disease. Published in Cell, the study shows that these antibodies, isolated from a recovered patient, target the conserved viral protein A35, halting infection in lab models and fully protecting rodents. Importantly, individuals recovering from mpox naturally produce these antibodies, and their presence correlates with milder illness and fewer hospitalizations. With no approved drugs for mpox and failed clinical trials of existing candidates, this discovery offers a promising pathway toward targeted therapies that could address urgent global health and biodefense needs.

Whatever happened to mpox? Is it still a threat?

September 2, 2025

Mpox remains a global health emergency nearly a year after Africa CDC and WHO issued their highest alerts, yet the disease has faded from headlines. In Kenya and across Africa, the virus has spread widely, with over 100,000 suspected cases this year. Despite $1.1 billion in pledged support, vaccine delivery has lagged, with many U.S.-donated doses now expired. Experts warn that inconsistent data, weak surveillance, and funding cuts leave the world “walking blind.” Progress in lab capacity and vaccine approvals offers hope, but the sluggish response risks entrenching mpox as a permanent threat with global consequences.

Mpox Progress Credited to Improved Diagnostics and Training

September 2, 2025

One year after mpox was declared a continental emergency, Africa is reporting measurable progress. Coordinated action between Africa CDC, WHO, governments, and communities has expanded laboratory capacity from only a few sites to nearly 70 in the DRC and 56 in Burundi, while more than 6 million vaccines have been distributed. Confirmed cases dropped 34.5 percent in the past six weeks, with major declines in the DRC, Sierra Leone, Uganda, and Burundi. Despite challenges such as funding gaps, stigma, and conflict in eastern DRC, strengthened surveillance, vaccination, and community engagement show Africa is building lasting resilience against mpox.

Nigeria Scales Up Mpox Prevention with Targeted Vaccination in High-Burden States

September 1, 2025

Nigeria’s targeted mpox vaccination campaign marks a vital step in protecting high-risk groups and reinforcing outbreak response across 12 states. Backed by WHO, UNICEF, and Gavi, the campaign is deploying 30,100 MVA-BN doses to frontline workers, immunocompromised individuals, and those exposed to confirmed cases. With mpox resurging after decades of absence and recent spikes in cases and deaths, the initiative is timely and strategic. Community voices reflect growing trust in vaccines, while officials emphasize cross-border health security. Early results show strong uptake, reinforcing the importance of collaboration, surveillance, and vaccination in curbing transmission and safeguarding vulnerable populations.

Mpox Cases Rise in Ghana, Philippines and China – But Decline Overall

August 29, 2025

Ghana is now at the center of Africa’s mpox crisis, reporting an 87 percent jump in confirmed cases in just one week. While overall cases across the continent have declined since the peak of the epidemic, localized surges in Ghana, Guinea, and several East African nations highlight the continued threat. Globally, new spikes in the Philippines and China remind us that mpox is not contained to Africa. With clade Ib infections linked to travel and active community transmission persisting in Central Africa, vigilance, vaccine access, and coordinated international response remain critical to preventing another global resurgence of this evolving virus.

Mpox Death in Mice Prevented by Antibodies Targeting A35 Protein

August 27, 2025

The recent discovery of human monoclonal antibodies targeting the mpox viral protein A35 marks a major step forward in the search for effective treatments against orthopoxviruses. Researchers at Mount Sinai found that these antibodies not only blocked viral spread in the lab but also protected rodents from severe disease and death. Importantly, A35 is highly conserved across the poxvirus family, reducing the likelihood of mutations that escape immune defenses. This breakthrough opens the door to promising therapeutic candidates that could be tested in humans and underscores the critical role of antibody research in combating the ongoing mpox resurgence.

Novel monoclonal antibodies show promise in preventing severe mpox disease

August 26, 2025

The discovery of three potent monoclonal antibodies against mpox by researchers at the Icahn School of Medicine at Mount Sinai offers a breakthrough in combating a virus that still lacks effective treatment. Targeting the highly conserved A35 viral protein, these antibodies not only blocked mpox spread in vitro but also protected rodents from severe disease and death. Importantly, people recovering from mpox consistently carried these antibodies, linking them to milder illness and no hospitalization. While clinical trials are still needed, this research highlights the potential for next-generation antibody therapies that could transform mpox treatment and strengthen defenses against orthopoxviruses.

Senegal reports mpox case, patient in isolation

August 25, 2025

Senegal’s detection of its first mpox case this year highlights the continuing vulnerability of West Africa to viral outbreaks. The patient, a foreign national, remains in stable condition under isolation, while 25 contacts are being closely monitored. Although no new cases have been confirmed, the event underscores the importance of vigilant surveillance, swift isolation, and community awareness to contain potential spread. With the World Health Organization maintaining mpox as a global public health emergency, Senegal’s rapid response demonstrates the critical role of national preparedness. Regional collaboration and consistent monitoring remain essential to safeguard against further transmission across West Africa.

Mpox deaths, Kenya surge among top concerns in Africa's outbreaks

August 21, 2025

Africa has made progress against mpox, with a 70 percent decline in confirmed cases, but challenges remain. Rising deaths, especially among people with HIV, highlight the need for stronger patient support, including food security. Kenya’s situation is especially concerning as cases spread from coastal areas to Nairobi, raising fears of exponential urban transmission. The Democratic Republic of the Congo shows improvement but continues to face regional spread and animal reservoirs. Promising vaccine campaigns, including U.S. support and Japan’s donation of LC16 for children, bring hope. Sustained vigilance, resources, and coordinated vaccination remain essential to containing the continent’s mpox outbreaks.

How a new global vaccine stockpile will help to counter the ongoing mpox threat

August 19, 2025

One year after mpox was declared a global health emergency, outbreaks persist across Africa, underscoring the need for faster and more reliable vaccine access. Gavi’s decision to establish a dedicated mpox vaccine stockpile marks a turning point. By securing supply in advance and shaping demand for manufacturers, Gavi aims to ensure timely response and equitable distribution, especially for low-income countries. While vaccines are critical, the World Health Organization stresses that stronger surveillance, case management, and community engagement remain essential. With cases still rising in conflict-affected areas like the Democratic Republic of the Congo, global coordination and sustained investment are vital.

Mpox in Malawi: A Community Effort That Proved It Can Be Beaten

August 18, 2025

Malawi’s experience with mpox highlights the power of community-driven response. When a 2-year-old boy in Mangochi District was confirmed as the country’s first case, health workers and local leaders mobilized quickly. Without a formal isolation center, the community itself became the frontline of prevention through contact tracing, household education, and improved hygiene practices. Importantly, the family received support rather than stigma, ensuring cooperation. With only three confirmed cases to date and no deaths, Malawi’s early response demonstrates that coordinated action between health authorities and communities can halt transmission and protect lives, even with limited resources.

Mpox Cases Are Rising in San Francisco Again. From Symptoms to Vaccines, What to Know for Summer 2025

August 15, 2025

Mpox is rising again in San Francisco, where cases have spiked from one per month to 14 since late June. All involve clade II, the strain behind the city’s 2022 outbreak. Most recent infections are mild and in people who were already fully vaccinated, underscoring that vaccines do not eliminate risk but greatly reduce severity. Health officials emphasize that gay and bisexual men, as well as trans and nonbinary individuals, remain the most affected. With summer gatherings and travel underway, targeted vaccination, community awareness, and continued surveillance are critical to prevent a larger resurgence of mpox in the Bay Area.

EU Health Task Force deploys ECDC experts to Sierra Leone to support the mpox outbreak response

August 15, 2025

Sierra Leone is mobilizing against its mpox outbreak with targeted international support. A two-week mission has deployed an epidemiologist and a risk communicator to work alongside the Ministry of Health, Africa CDC, and local leaders. Their work focuses on outbreak investigation, data-driven strategies, and culturally tailored public health messaging. Paramount chiefs and district councils are also engaged to build trust and strengthen community responses. As the country reviews its three-month Action Plan, sustained collaboration between technical experts and local stakeholders will be vital. Success in Sierra Leone could provide a model for effective, community-based outbreak control across Africa.

Vaccination, funding gaps remain challenge to fight against mpox in Africa: WHO

August 14, 2025

One year after mpox was declared a global health emergency, Africa continues to face serious challenges. The World Health Organization reports more than 174,000 suspected cases and nearly 50,000 confirmed infections across 28 countries, with 240 deaths. Although weekly cases have declined by one third and 900,000 people have received at least one vaccine dose, access remains far below need. Limited supplies, funding gaps, and stigma hinder progress, particularly in high-risk areas. Sustained community surveillance, targeted vaccination, and integration into broader health systems will be essential to prevent resurgence and to build a durable, equitable response.

This virus seems like it's no longer a problem. It's still a threat

August 14, 2025

Mpox may seem like yesterday’s crisis, but Africa is living its resurgence. New data from the Africa CDC show outbreaks in 24 countries, nearly double the number affected a year ago. A virulent strain, clade 1b, has spread rapidly from eastern Democratic Republic of Congo into neighboring nations, fueled by conflict, mobility, and gaps in care. Nearly 97,000 suspected cases and 600 deaths have been reported this year, though experts warn the real toll is far higher. Yet fewer than one million people across the continent have been vaccinated. Global promises remain unmet, leaving Africa dangerously exposed to preventable tragedy.

Africa’s Mpox Response: Better Diagnostics One Year into Emergency

August 14, 2025

Mpox cases are finally declining across Africa, but experts caution that the crisis is far from over. In the Democratic Republic of Congo, the epicenter of the outbreak, diagnostic capacity has expanded from just two laboratories in 2024 to 69 this year. More than 886,000 people have been vaccinated in 12 countries, yet coverage remains insufficient against nearly 100,000 suspected cases. Conflict, stigma, and vaccine shortages still hinder control efforts, while cholera outbreaks further strain fragile systems. Sustaining progress requires continued investment in surveillance, rapid diagnostics, and targeted vaccination. Without sustained global support, fragile gains risk slipping away.

Sustaining efforts to end mpox outbreaks in Africa

August 14, 2025

One year after the World Health Organization declared mpox a global health emergency, Africa has made measurable progress but faces ongoing risks. Twenty-eight countries have reported more than 174,000 suspected cases and nearly 50,000 confirmed infections, with 240 deaths. Coordinated action has expanded laboratories, scaled vaccination, and improved care. Over 900,000 people have received at least one vaccine dose, and some countries have gone months without new cases. Yet conflict in eastern Democratic Republic of Congo, persistent stigma, and limited funding threaten fragile gains. Sustained surveillance, targeted vaccination, and investment in community engagement remain essential to prevent resurgence.

Mpox Crisis Deepens: Scientist Warns “We Need To Get Things Under Control”

August 13, 2025

Mpox is no longer confined to remote corners of the Democratic Republic of Congo. New data show it is spreading into cities like Kinshasa and shifting from wildlife-driven transmission to sustained human-to-human spread. A University of Manitoba researcher, Dr. Jason Kindrachuk, and colleagues warn that younger adults, including sex workers, are increasingly affected, with cases marked by genital lesions suggestive of sexual transmission. Alarming evidence also shows in utero transmission during pregnancy. Although severity remains low in some outbreaks, the virus’s expansion into dense urban centers raises urgent questions. Global preparedness and targeted interventions, including vaccines for high-risk groups, are essential.

How WHO helped in Moyale city fight a Mpox outbreak

August 12, 2025

The rapid Mpox outbreak in Moyale, Ethiopia, underscored the dangers of cross-border transmission in high-traffic regions. Swift action by the Ethiopian Ministry of Health, supported by WHO, demonstrated the power of coordinated response. Isolation units, targeted community education, and active surveillance curbed further spread. Integrating mental health support and engaging religious leaders reduced stigma and encouraged testing. By prioritizing border screening, multilingual communication, and local volunteer training, the response not only contained the outbreak but also strengthened long-term community resilience. Moyale’s experience highlights that preparedness, trust, and sustained collaboration are essential to managing infectious threats in vulnerable, interconnected regions.

Inside the Red Zone: Sierra Leone’s terrifying mpox outbreak

August 11, 2025

Sierra Leone’s worst mpox outbreak has infected over 5,000 people and killed at least 47 since late 2024, overwhelming its fragile health system. Initially encouraging home isolation, the government reversed course, mandating treatment in designated centers, combining this with vaccination and outreach to curb stigma. Cases have since dropped sharply, though facilities still see steady admissions. Challenges persist: delayed care due to fear, mistrust, traditional healer use, and limited resources. The outbreak shows Clade IIb’s potential for widespread, nonsexual transmission in high-density, low-resource settings. Sustained surveillance, vaccination, and community engagement are essential to prevent resurgence and contain future high-consequence pathogen threats.

Mpox cases drop, new outbreaks detected — Africa CDC

August 8, 2025

Africa has seen a 58 percent drop in mpox cases from May to late July 2025, a milestone credited to strong national leadership, community engagement, and improved health systems. Over 3.1 million vaccine doses have been distributed, with 886,000 people vaccinated, most in the Democratic Republic of the Congo. However, new outbreaks in Gambia, Cameroon, and Mozambique, along with detection of high-risk clade IIb in Kinshasa, highlight the need for vigilance. Africa CDC is also responding to cholera in 23 member states, driven by poor water and sanitation. Coordinated surveillance, targeted vaccinations, and integrated case management remain essential to sustain progress.

Mixed mpox picture in Africa shows successes, but challenges in newly affected countries

August 7, 2025

Africa’s mpox cases are trending down overall, but fresh concerns are emerging. Africa CDC reports exponential spread in Guinea, detection of clade 2b in the DRC’s Kinshasa, and rising cases in Liberia, Mozambique, and several newly affected nations. While Sierra Leone’s sharp decline—from 600 to 94 weekly cases—highlights the impact of strong surveillance and vaccination, other countries face resource gaps, weak health systems, and low community awareness. Liberia’s test positivity has surged to 72%, and Mozambique is reporting cross-district spread. These developments underscore the need for rapid case detection, targeted vaccination, and reinforced surveillance to contain evolving transmission patterns.

Mpox testing initiative launched in Africa as outbreaks continue

August 1, 2025

Africa CDC and the European Commission have launched PAMTA, a €9.4 million initiative to expand mpox diagnostics, genomic sequencing, and local test kit manufacturing across Africa. Announced as Gambia became the 25th affected country, PAMTA supports over 150,000 tests, with the goal of boosting surveillance, resilience, and rapid response. The latest data shows over 91,000 suspected mpox cases and 667 deaths in 2025 alone. As community spread of clade 1b surges in nations like Uganda and Mozambique, PAMTA's integrated approach marks a critical turning point in Africa–EU health security cooperation and sustainable outbreak management.

EU and Africa to ramp up Mpox testing

August 1, 2025

Amid vaccine shortages and low testing rates, the European Commission and Africa CDC have launched the €9.4 million PAMTA initiative to expand mpox diagnostics across Africa. This EU-funded effort aims to provide over 150,000 tests and foster local kit manufacturing to address rising case numbers, particularly in the DRC. While 2.9 million vaccines were pledged globally, only 664,000 people have been vaccinated, falling far short of the 6.4 million doses needed. PAMTA marks a strategic shift—underscoring EU–Africa collaboration on public health resilience and the importance of timely testing, manufacturing, and surveillance to manage outbreaks.

Africa CDC and European Commission Launch New Initiative to Strengthen Mpox Testing and Sequencing Across Africa

July 31, 2025

The launch of the Partnership to Accelerate Mpox Testing and Sequencing in Africa (PAMTA) marks a major milestone in EU–Africa health cooperation. With €9.4 million in co-funding from the EU4Health 2024 Work Programme, the initiative aims to deliver over 150,000 mpox tests, boost genomic sequencing, train health workers, and promote local test kit manufacturing. Led by Africa CDC and ASLM, PAMTA will close diagnostic gaps and reinforce outbreak resilience across the continent. As Africa grapples with ongoing mpox outbreaks, this partnership sets a vital precedent for self-reliant, continent-wide epidemic preparedness and real-time surveillance infrastructure.

GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains

July 30, 2025

As mpox Clade I spreads across continents and global biosecurity threats grow, GeoVax Labs has renewed its call for decisive U.S. action to modernize vaccine preparedness. The company warns that continued dependence on a single foreign supplier for MVA-based mpox vaccines jeopardizes national readiness. GeoVax’s domestically produced candidates—including GEO-MVA for mpox and GEO-CM04S1 for COVID-19—offer scalable, broad-spectrum protection. With bipartisan momentum for domestic biodefense, GeoVax urges federal investment in onshore manufacturing, diversified platforms, and procurement before the next outbreak. As Chairman David Dodd states, “The cost of delay is steep, and the status quo is unacceptable.”

Fulton County Health Officials Warn Mpox Isn’t Just in the Past

July 29, 2025

Mpox remains a persistent concern in Fulton County, Georgia, despite reduced national attention since the 2022 outbreak. Fulton reported 48 new cases between July 2024 and June 2025, with 96% affecting men—predominantly Black gay men, many living with HIV or experiencing homelessness. Public health officials urge vaccination among at-risk groups amid fears that HIV-related budget cuts could undermine outbreak response capacity. As Fulton’s director of epidemiology emphasized, the virus is still circulating, and systemic inequities continue to shape outcomes. Without adequate resources, public health infrastructure may be unprepared for future mpox resurgences—or any other viral threats.

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

July 28, 2025

Emergent BioSolutions has released a comprehensive review of brincidofovir’s potential role in mpox treatment, published in Expert Review of Anti-infective Therapy. The article outlines preclinical and clinical data, highlights the investigational use of brincidofovir in both adults and children, and discusses potential combination therapy with tecovirimat. Brincidofovir is currently under evaluation in the MOSA trial—a double-blind, placebo-controlled study launched in January 2025 across Africa. With mpox still classified as a global public health emergency, this review underscores the urgency of identifying safe, effective treatments and supports evidence-based collaboration across emerging infectious disease platforms.

In Uganda a new epidemic alert system is helping fight mpox

July 28, 2025

In Uganda’s Wakiso District, frontline health workers like Edith Nalunga are redefining outbreak response. Using a simple SMS-based alert system, Nalunga rapidly responds to suspected mpox cases, blending community education with public health surveillance. Her recent field visit—prompted by code “6767”—underscores how localized knowledge and empathy strengthen containment efforts. As Uganda battles 7,400 confirmed mpox cases and 44 deaths since July 2024, Nalunga’s approach exemplifies the essential role of grassroots health systems. Public awareness, not just isolation, remains the linchpin of successful prevention. Her work reminds us: epidemic control begins not in labs—but at the doorsteps of vulnerable families.

WHO Urges Rapid Treatment for Concurrent HIV and Mpox

July 28, 2025

The World Health Organization has issued updated guidance urging rapid initiation of antiretroviral therapy (ART) for people living with HIV who are diagnosed with mpox. The recommendation—presented at the 2025 International AIDS Society Conference—emphasizes that ART should ideally begin within seven days of HIV diagnosis. People with low CD4 counts are at particular risk for severe mpox illness and death, underscoring the urgency of early HIV treatment in co-infected patients. While data on immune reconstitution inflammatory syndrome remain limited, WHO asserts that the clear benefits of early ART outweigh the risks, marking a vital step toward integrated viral care.

Ghana records first Mpox death as cases surge

July 27, 2025

Ghana has reported its first mpox-related death amid a sharp rise in infections, with 23 new cases last week bringing the national total to 257. This marks the country's highest weekly increase since the virus emerged in June 2022. Health Minister Akandoh assured the public that the outbreak is under control and emphasized the importance of early detection and responsible behavior. With vaccine doses from WHO expected imminently, officials are preparing to immunize at-risk populations. Ghana’s growing case count mirrors a concerning trend across West Africa, where mpox continues to spread, reinforcing the urgency for timely vaccination and regional coordination.

Mpox isn’t gone as virus continues to spread in Africa

July 25, 2025

Pride is a time to celebrate authenticity—and part of that celebration includes caring for ourselves and each other. With mpox cases resurging globally and vaccine uptake still lagging in the U.S., open, stigma-free dialogue about health remains vital. Mpox disproportionately affects LGBTQ+ communities, particularly those with uncontrolled HIV, but it’s a public health concern for all. Vaccination, symptom awareness, and compassionate communication are powerful tools. This summer, let’s continue to look out for one another—not just through parties and parades, but through the conversations that keep our communities informed, safe, and empowered. Pride is protection, too.

EMA Launches Review of Tecovirimat Effectiveness for Mpox

July 25, 2025

The European Medicines Agency’s review of Tecovirimat (TPOXX) marks a critical inflection point in the treatment of mpox. Once fast-tracked for emergency use, Tecovirimat’s approval was based on surrogate markers rather than demonstrated clinical efficacy. Now, new trial data from PALM007, STOMP, and UNITY trials show little to no advantage in healing time or symptom resolution, prompting a re-evaluation of its risk-benefit profile. As mpox continues to spread, particularly among high-risk populations, robust, evidence-based therapeutics are urgently needed. Regulators and public health agencies must ensure future responses are grounded in both science and transparency—not just speed.

Africa CDC warns of exponential mpox spread in Guinea

July 24, 2025

Mpox continues to evolve into a widespread and complex public health emergency across Africa. Guinea is now facing exponential case growth, mirroring earlier surges in Sierra Leone. While countries like the DRC and Uganda are seeing declines, cases are rising in West African transit hubs like Togo and Kenya, raising concerns about regional spread. Vaccine supply is critically low, with 800,000 doses available but inaccessible due to funding cuts. Africa CDC estimates 3.4 million doses are needed now. Global inaction at this stage risks losing control of emerging hotspots. Early, well-funded intervention remains the clearest path to containment.

West Africa's Clade II Mpox Outbreak Expands

July 23, 2025

The World Health Organization’s recent decision to maintain mpox as a Public Health Emergency of International Concern underscores the virus’s persistent and evolving threat, particularly in West and Central Africa. With Clade II outbreaks now endemic in Liberia and Sierra Leone and Clade I cases confirmed in Cameroon, the virus is spreading across gender lines and through both sexual and nonsexual contact. The CDC has issued Level 2 travel advisories and recommends mpox vaccination for travelers to the region. As Africa draws increasing global tourism, preemptive vaccination and education must become core strategies to mitigate risk and contain further transmission.

Hundreds of thousands of US taxpayer-funded vaccine doses may expire, lawmakers say

July 23, 2025

Nearly 800,000 U.S.-pledged mpox vaccine doses sit in warehouses at risk of expiry—an unfolding failure flagged by 48 congressional Democrats. Their letter to the State Department warns of moral, strategic, and public health consequences if doses are not shipped immediately. This comes amid deep foreign aid cuts under the Trump administration, which have paralyzed global humanitarian operations. Africa’s mpox crisis, especially in the DRC, Uganda, and Burundi, continues unabated. The WHO still classifies mpox as a global health emergency. Letting vaccines expire is not just wasteful—it’s an abandonment of global responsibility when urgency demands action.

Mozambique reports its first mpox cases of the year as infections rise in parts of Africa

July 17, 2025

Mozambique’s confirmation of its first mpox cases this year marks the 24th African country now contending with outbreaks. While cases decline in high-burden nations like Sierra Leone and the DRC, troubling increases persist in Nigeria, Liberia, Zambia, Kenya, and Guinea. A severe vaccine shortage threatens these fragile gains, as funding gaps have delayed distribution of urgently needed doses. Africa CDC estimates 3.4 million doses are required, yet shelf lives are expiring amid stalled U.S. pledges and UNICEF procurement delays. Without sustained investment, these outbreaks risk spreading unchecked. Vaccine equity is not optional—it’s imperative.

Mpox Antiviral Clinical Trial Advances as WHO Extends Global Emergency

July 17, 2025

As the World Health Organization extends mpox’s global emergency status, NanoViricides’ NV-387 enters final preparations for Phase II clinical trials. Targeting Clade Ia and Ib monkeypox virus strains in Central Africa, NV-387 is an orally administered, host-mimetic antiviral designed to block viral entry at conserved host cell receptors. With no approved treatment proven effective in humans, NV-387 offers a potential breakthrough. Its unique design may limit viral resistance and provides a practical formulation for symptomatic patients. If successful, NV-387 could become the first antiviral with demonstrated efficacy against mpox, and a valuable addition to global bioterrorism preparedness.

US has wasted hundreds of thousands of vaccines meant for Africa, health officials there say

July 17, 2025

Nearly 800,000 mpox vaccine doses pledged by the U.S. to African nations may be discarded due to expiration, reflecting systemic failures in global outbreak response. Africa CDC cites short shelf lives and bureaucratic bottlenecks, including U.S. foreign aid cuts, as key obstacles. Meanwhile, nearly 160,000 suspected cases and 1,900 potential deaths—many among children—underscore the crisis. Vaccines exist, but broken mechanisms prevent their use. In a pandemic era defined by equity rhetoric, the silent expiry of life-saving tools speaks volumes. Public health cannot hinge on expired promises.

WHO recommends rapid treatment initiation for people living with HIV and mpox

July 16, 2025

In its May 2025 guideline update, the World Health Organization (WHO) strongly recommends rapid initiation of antiretroviral therapy (ART) for individuals living with HIV who are diagnosed with mpox. This aligns with WHO’s broader strategy promoting same-day ART to reduce mortality and achieve viral suppression. People with advanced HIV, particularly those with CD4 counts below 200 cells/mm³, face significantly higher risks of severe mpox outcomes. WHO’s guidance also urges early HIV and syphilis testing in all suspected mpox cases, reinforcing the need for integrated care approaches to improve survival and reduce complications in co-infected patients.

WHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely

July 16, 2025

With the World Health Organization extending mpox’s public health emergency status in July 2025, NanoViricides, Inc. reaffirmed the importance of its candidate NV-387. Positioned as a broad-spectrum, host-mimetic antiviral, NV-387 is designed to block viral entry by mimicking human cell receptors, potentially limiting viral escape through mutation. Unlike prior antivirals like tecovirimat or brincidofovir, which have shown limited efficacy or adverse effects in mpox patients, NV-387 showed strong safety signals in Phase I trials. NanoViricides plans to launch a Phase II trial in Africa to assess dosing and efficacy. Success could unlock broader pandemic preparedness and bioterrorism market opportunities.

4 new Mpox cases reported in Taiwan, risks high until September: CDC

July 15, 2025

Taiwan’s Centers for Disease Control has confirmed four new mpox cases, including one imported from China, signaling elevated transmission risk through September. All cases involved unvaccinated men in their 30s who developed classic symptoms such as rashes and pustules. Authorities warn that increased summer travel and social gatherings heighten outbreak potential. Since June 2022, Taiwan has reported 473 cases—exclusively of the Clade IIb strain. Vaccination uptake has reached over 99,000 first doses and 68,000 second doses, but continued outreach is vital. The CDC urges at-risk individuals to vaccinate promptly, as two doses reduce severe illness and death by up to 90%.

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387

July 14, 2025

NanoViricides, Inc. is preparing to launch a Phase II adaptive clinical trial of its antiviral candidate NV-387 for Clade Ia and Ib mpox, aiming to evaluate safety, dosing, and efficacy. The trial will begin in the Democratic Republic of the Congo and use a dissolvable oral gummy formulation to ease administration in patients with painful lesions. If successful, NV-387 could become the first human-tested antiviral for orthopoxviruses. This trial arrives as existing options like tecovirimat have underperformed, and Clade I mpox remains a growing global concern. Further support and scrutiny will be crucial as the study advances.

Should the USA Follow France By Offering Mpox Boosters

July 11, 2025

As the World Health Organization maintains mpox as a public health emergency of international concern, debate grows over the need for booster doses of the JYNNEOS vaccine. France has recommended a third dose for high-risk individuals, citing stronger antibody persistence. However, the U.S. Centers for Disease Control and Prevention (CDC) remains cautious, citing low breakthrough rates and mild disease in vaccinated individuals. A recent African preprint study supports long-term immune memory from the two-dose series but notes increased side effects with boosters. As global cases rise, public health agencies must weigh evolving evidence to shape booster strategies grounded in risk.

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

July 10, 2025

Tonix Pharmaceuticals has presented compelling preclinical data on TNX-801, a recombinant horsepox vaccine designed for mpox and smallpox prevention. At the 2025 Vaccine Congress, researchers highlighted TNX-801’s capacity to generate durable immunity from a single subcutaneous dose—offering strong protection without the safety risks associated with traditional vaccinia vaccines. In nonhuman primates, TNX-801 conferred complete protection against Clade I mpox challenge. With promising immunogenicity and attenuation, TNX-801 could be a game-changer in outbreak preparedness. Tonix aims to move into clinical trials soon, positioning this novel candidate as a critical asset in global orthopox virus control strategies.

Mpox cases rise in handful of Africa's outbreak countries

July 10, 2025

As mpox cases decline in Sierra Leone and the Democratic Republic of the Congo, the Africa CDC warns of new surges in Burundi, Uganda, Ghana, Kenya, Liberia, and Guinea. With 23 countries reporting outbreaks this year and 18 still active, the epidemic remains highly dynamic. Increases in Uganda and Burundi signal waning public vigilance, while Ghana and Kenya are facing rapid spread and wider community transmission. Vaccine shortages remain a critical barrier to containment beyond Sierra Leone, which has vaccinated over 120,000 people. The continent’s patchwork of responses underscores the urgent need for sustained surveillance, community engagement, and equitable vaccine access.

Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country

July 9, 2025

Bavarian Nordic has secured a major contract exceeding DKK 200 million to supply its MVA-BN® smallpox/mpox vaccine to a European nation in 2025, reinforcing efforts to bolster public health security amid rising biological threats. The MVA-BN vaccine, already approved across multiple global markets, serves as a cornerstone for both mpox outbreak response and smallpox preparedness. This order brings Bavarian Nordic’s 2025 public preparedness contracts to over DKK 3 billion. CEO Paul Chaplin emphasized the strategic importance of vaccine readiness in strengthening geopolitical resilience, highlighting continued EU and global partnerships to ensure access to medical countermeasures in a volatile health landscape.

Wayne State part of $3.5 million NIH grant to help develop treatment for mpox

July 9, 2025

A new $3.5 million NIH grant to Wayne State University and UCLA researchers marks a critical step in understanding and combating ocular complications from mpox. As Clade IIb spreads globally, this five-year study will investigate how the virus targets eye tissues, its evolving genetic mutations, and novel antiviral treatments. By combining biosafety level 2 and 3 lab expertise, the project aims to preempt severe eye-related disease outcomes. This collaboration reinforces that pandemic preparedness depends on proactive, cross-institutional research. With the virus rapidly evolving, sustained investment in both scientific inquiry and therapeutic development is imperative for safeguarding public health.

Responding to an mpox outbreak in the heart of Sierra Leone

July 8, 2025

As mpox continues to surge across Sierra Leone, MSF is leading a critical response effort in high-burden districts like Freetown, Bombali, and Kenema. With over 4,000 confirmed cases, stigma, misinformation, and delayed care are fueling preventable suffering, especially for those with painful, advanced disease. MSF’s work—rehabilitating isolation wards, training health workers, supporting psychosocial care, and building diagnostic capacity—is helping restore public trust and improve treatment outcomes. But with every delay, the virus spreads further. The international community must prioritize sustained support for local responders who are battling not only a virus, but also fear, stigma, and resource constraints.

New Multi-Epitope Mpox Vaccine Shows Strong Potential in Silico

July 8, 2025

A new computational vaccine blueprint from University of Dhaka researchers offers promise against monkeypox (mpox), leveraging reverse vaccinology to design a multi-epitope vaccine (MEV) targeting conserved MPXV proteins. In silico modeling revealed strong immune receptor binding and robust T- and B-cell responses, marking a potential leap beyond existing smallpox-based formulations. However, while the immunoinformatics approach is timely amid the Clade Ib resurgence in Africa, no experimental validation has yet been conducted. Further in vitro and in vivo testing is essential before clinical viability can be assessed. This research underscores the power of bioinformatics in pandemic preparedness and next-generation vaccine development.

Management of mpox following removal of HCID status

July 7, 2025

In March 2025, UK public health authorities reclassified all clades of mpox as no longer meeting criteria for high consequence infectious disease (HCID), citing low fatality rates, limited local transmission, and effective vaccine availability. Despite this, public health oversight remains robust. Clinicians are advised to maintain vigilance in diagnosing and managing suspected mpox cases, particularly among vulnerable groups. Updated infection prevention, isolation, and notification protocols remain in place across hospital, community, and home settings. The strategic goal is still elimination of person-to-person transmission, supported by vaccination, clear clinical guidance, and enhanced occupational safety standards for healthcare providers.

Mpox cases decline in Sierra Leone as Africa faces shortage in vaccine funding

July 3, 2025

Sierra Leone's declining mpox cases mark a promising shift in West Africa's outbreak trajectory. The Africa CDC credits this trend to expanded community health worker engagement and effective pairing of vaccination with contact tracing. Yet, a deeper crisis is looming—vaccine stocks are available, but funding has dried up. UNICEF and other procurement partners lack the resources to purchase and distribute doses, even as demand and uptake rise in affected communities. As outbreaks stabilize, the absence of timely investment could undermine hard-won progress. Equity in global health must extend beyond words—resource mobilization is now the critical next step.

WHO donates medical supplies and equipment to boost mpox response

July 3, 2025

WHO has stepped up its support to Sierra Leone’s mpox response with a donation of essential medical supplies, test kits, laboratory equipment, and five medical-grade refrigerators valued at over $126,000. The delivery comes at a pivotal moment as the country battles over 4,000 confirmed mpox cases. The supplies will boost diagnostic and case management capabilities at key treatment sites, including the Hastings Treatment Centre. WHO Country Representative Dr. George Ameh emphasized that the donation reflects a commitment to empowering frontline workers. This contribution not only strengthens the outbreak response but also reinforces long-term health system resilience.

WHO-backed integrated testing model strengthens response to mpox, HIV, and syphilis

July 2, 2025

As mpox cases climb in Central Africa, the Democratic Republic of the Congo (DRC) is setting a precedent with its integrated HIV and syphilis testing program within mpox care. Backed by WHO, the initiative enhances early diagnosis and treatment, especially for high-risk populations. Initial results from Kinshasa show promising uptake and improved case detection. Yet, stock-outs and limited treatment sites highlight the fragility of health infrastructure. The DRC’s approach is a replicable model for resource-limited settings, showing that public health responses to outbreaks can—and must—bridge gaps in broader disease surveillance and care.

Routine vaccination holds key to reducing future mpox outbreaks in England, say researchers

July 2, 2025

New research co-led by the University of Bristol and UK Health Security Agency confirms that routine mpox vaccination programs for gay and bisexual men are both cost-effective and life-saving. The study found that continuous vaccination, with targeted intensification during outbreaks, could cut projected cases in England from 11,000 to 1,000 over a decade while saving the NHS £9 million. As Clade Ib spreads in Sub-Saharan Africa, this model demonstrates the global value of proactive, targeted public health strategies. Ensuring continued access to vaccination is essential to reduce mpox transmission, protect high-risk groups, and preserve public health resources.

Using viral load tests to help predict mpox severity when skin lesions first appear

July 2, 2025

A new study led by Nagoya University offers promising insights into mpox clinical care. Researchers found that measuring viral loads in blood at the onset of skin lesions can predict disease severity in clade I mpox patients. Using data from the Democratic Republic of the Congo, the team identified a threshold—40,000 viral copies per milliliter—beyond which patients are more likely to experience severe, long-lasting symptoms. These findings could help health workers triage patients early and better allocate resources. As the clade I outbreak spreads across Africa, this method may enable faster, more personalized care and improve containment efforts.

UCLA-led team receives $3.5 million NIH grant to develop treatment for mpox: What to know about the viral illness

July 2, 2025

With a new $3.5 million NIH grant, researchers at UCLA and Wayne State University are advancing vital mpox research amid a troubling resurgence in Africa. Their work targets a fast-evolving clade of the virus that disproportionately affects children and poses increasing global risk. By studying viral mutations, eye and skin tissue infection pathways, and testing promising antiviral drug candidates that restore immune function, the team aims to curb transmission and reduce severity. As the U.S. sees sporadic mpox cases, this forward-looking investment is a crucial step toward global preparedness—because ignoring viral threats today could spark tomorrow’s crisis.

GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives

July 2, 2025

GeoVax’s GEO-MVA vaccine, targeting mpox and smallpox, is gaining momentum as a critical public health asset amid new outbreaks in the U.S., Europe, and Africa. Backed by favorable guidance from the European Medicines Agency (EMA), the vaccine is on an expedited track toward regulatory approval. Its scalable, avian cell-based production platform promises greater manufacturing flexibility and cost-efficiency, addressing the urgent global need for diversified MVA vaccine supply. GeoVax’s pursuit of a BARDA-funded partnership further positions it as a vital complement—or alternative—to current vaccine monopolies. With regulatory and strategic momentum, GEO-MVA may help meet mounting demand in a multipolar outbreak landscape.

New study finds routine vaccination holds key to reducing future mpox outbreaks in England

July 2, 2025

A UK-based study co-led by the University of Bristol and UKHSA finds that routine and surge mpox vaccination strategies among gay and bisexual men are not only life-saving but cost-saving. Modelling suggests such approaches could prevent 10,000 infections and save £9 million over ten years. The research highlights the long-term health and financial benefits of continuous mpox vaccination, especially for at-risk groups. With clade Ib spreading in sub-Saharan Africa and mpox still a global concern, this evidence strongly supports preemptive vaccination policies. Proactive immunization is a prudent investment in public health—not just prevention, but protection and preparedness for future outbreaks.

Taiwan reports highest weekly Mpox cases so far this year

July 1, 2025

Taiwan is witnessing its highest weekly count of locally transmitted mpox cases this year, with four new infections confirmed between June 24 and July 1, all involving men in their 30s. The Taiwan Centers for Disease Control attributes these cases to intimate contact through dating apps, complicating contact tracing. With only 68,193 individuals having completed the two-dose mpox vaccine regimen, public health officials urge full vaccination, especially amid the summer transmission peak. As clade IIb continues to circulate globally, Taiwan’s experience reinforces the need for robust prevention strategies, targeted outreach to at-risk groups, and real-time surveillance to prevent further spread.

Mpox in Sierra Leone: Inside the response to a fast-moving outbreak

July 1, 2025

Sierra Leone is battling its worst mpox outbreak, with over 4,489 infections and 29 deaths since January. While the case fatality rate is low, rapid urban transmission is overwhelming the health system. Médecins Sans Frontières (MSF) has stepped in to support treatment, surveillance, and community outreach, including the establishment of a 50-bed treatment center and infection control efforts. However, stigma, misinformation, and vaccine shortages are undermining containment. As MSF stresses, sustained international assistance is crucial—not only to halt transmission in Sierra Leone but also to prevent further regional spread. This is a test of global solidarity and urgency.

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387

July 1, 2025

NanoViricides’ decision to prioritize mpox as the first indication for its broad-spectrum antiviral candidate NV-387 marks a critical step in epidemic preparedness. With Phase II clinical trials soon to begin in the Democratic Republic of Congo, this novel oral gummy formulation could address urgent treatment gaps, especially in low-resource settings. As other antivirals like tecovirimat fail to show efficacy, NV-387’s promising animal data and host-mimetic nanomedicine approach offer hope. If proven effective, NV-387 could not only fill a void in global mpox treatment but also earn a place in strategic national stockpiles for smallpox and bioterrorism defense.

Health officials encouraged by recent trends in Africa’s mpox outbreaks

June 30, 2025

Mpox trends in Africa show early signs of improvement, with Sierra Leone—once the continent’s largest hotspot—now reporting a relative decline in case share, from 63% to 41% of Africa’s total. Yet with a 91% test positivity rate and over 500 new cases per week, Africa CDC stresses that enhanced surveillance remains critical. Vaccination campaigns have reached nearly 700,000 people across seven countries, but the region still faces a steep shortfall from the 6.4 million doses it needs. As cases rise in Togo and persist in Uganda and the DRC, sustained investment in community health, testing, and vaccines is vital.

AHF Urges Vaccine Equity as Mpox Cases Surge in Sierra Leone

June 30, 2025

As Sierra Leone faces a severe mpox outbreak, accounting for 41% of Africa’s cases, AIDS Healthcare Foundation (AHF) is urging urgent global action. With just 40,000 vaccinated and over 4,300 confirmed cases, the response is overwhelmed. AHF calls on wealthy nations to donate vaccines and demands that Bavarian Nordic lower the cost of its Jynneos vaccine and share production technology with African manufacturers. With 6.4 million doses needed continent-wide, equity must drive the response. Mpox is not just Sierra Leone’s fight—it is a global health emergency that demands affordable tools and collective commitment to end preventable suffering.

Breakthrough Infection, Reinfection Rare but Possible After Mpox Infection or Vaccination

June 28, 2025

New findings from CROI 2025 confirm that mpox reinfection is rare, but not impossible—even among vaccinated individuals. Two studies show that vaccine-induced immunity wanes over time, particularly in people with HIV, and that prior infection does not guarantee lifelong protection. However, the CDC continues to recommend against vaccinating people who have already recovered from mpox, citing the rarity and mild nature of reinfections. These findings underscore the need for ongoing surveillance, research into booster strategies, and nuanced guidance for vulnerable populations, especially as mpox continues to evolve and circulate in both endemic and non-endemic settings.

Hoping that viruses will go away is not enough – what is needed is continuous vigilance

June 26, 2025

Sierra Leone’s growing mpox outbreak is a stark reminder that viruses don’t disappear—they adapt, persist, and resurface where surveillance falters. With over 3,000 confirmed cases and 15 deaths, and clade IIb likely the dominant strain, the country faces mounting strain despite strengthened response efforts. Children remain particularly vulnerable. The outbreak’s rapid spread underscores global risks: infectious threats do not respect borders. Investing in sustained surveillance, equitable vaccine access, and robust local health systems isn’t just ethical—it’s strategic. Sierra Leone’s crisis must catalyze global action before mpox’s resurgence becomes the next international failure of foresight.

Bavarian Nordic begins mpox vaccine trial in pregnant women and infants

June 26, 2025

In a critical move for protecting vulnerable populations, Bavarian Nordic has launched two Phase III trials of its mpox vaccine, Jynneos, in infants under two and pregnant or breastfeeding women in the Democratic Republic of the Congo. Supported by CEPI, EDCTP3, and led by institutions in Kinshasa and Antwerp, the studies will assess vaccine safety and immunogenicity. While this research is vital, funding shortfalls—especially the U.S. withdrawal from GAVI and USAID—threaten equitable access to future doses. The trials may help expand vaccine labels, but global cooperation and sustained financial support are essential to ensure protection reaches those most at risk.

Op-ed: Fighting an mpox outbreak, Sierra Leone ‘shouldn’t have to stand alone’

June 24, 2025

A dangerous mpox outbreak in Sierra Leone is escalating rapidly, with a highly transmissible variant spreading nationwide. Despite impressive local efforts in testing, contact tracing, and genomic surveillance, experts warn that international support is falling short. In a June 11 op-ed in Time, Harvard’s Pardis Sabeti and Christian Happi commend Sierra Leone’s preparedness but emphasize the urgent need for U.S. and global assistance. With disease cases doubling every two weeks and signs of international spread, the moment to act is now. Supporting Sierra Leone’s response is not just aid—it is strategic global health security.

England's Mpox Cases Continues in June 2025

June 24, 2025

England is taking proactive steps to contain rising mpox cases, particularly from the newly emerged clade Ib, with 12 cases confirmed as of May 2025. Most infections are linked to travel from endemic countries, underscoring global interconnectedness in disease spread. In response, England will launch a new routine vaccination campaign in August 2025, combining pre-exposure mpox and gonorrhoea immunizations through sexual health clinics. This integrated approach—backed by WHO concerns over sustained international mpox transmission—marks a critical evolution in STI prevention. England’s timely action could serve as a model for other nations facing imported cases of mpox.

Mpox in Sierra Leone: what’s behind the recent surge and why west Africa is at risk

June 23, 2025

With over 4,000 confirmed mpox cases and 25 deaths as of June 17, 2025, Sierra Leone is facing a rapidly escalating outbreak. Genomic sequencing is underway to trace the virus’s origin, but transmission—primarily among young adults and sex workers—is expanding quickly. As a key regional hub with high mobility, Sierra Leone’s outbreak poses a serious risk to neighboring countries like Liberia and Ghana. Local health authorities are implementing surveillance, contact tracing, and targeted vaccination, but resources remain limited. Without urgent international support, including more testing and vaccines, this could become West Africa’s next regional health crisis.

Sierra Leone’s Mpox Surge Puts Africa’s Epidemic Preparedness to the Test

June 16, 2025

Sierra Leone is confronting a major mpox outbreak, now the third largest in Africa, with over 4,000 confirmed cases. Despite activating a Level 2 emergency response and opening treatment centers, authorities face vaccine shortages and public reluctance toward care. This resurgence underscores regional vulnerability and the urgent need for coordinated leadership from institutions like WAHO and RCSDC. With outbreaks spreading to Togo, Ghana, and Liberia, a region-wide response is essential. Without sufficient vaccine access, funding, and surveillance, containment will falter. Regional solidarity and global investment must rise to meet the moment, turning this crisis into a foundation for lasting preparedness.

LGBTQ+ health centers lead fight against mpox and stigma nationwide

June 13, 2025

The LGBTQ+ community played a pivotal role in stopping the 2022 mpox outbreak in the U.S., not only by embracing safer practices but through the frontline response of community health centers. Clinics like Whitman-Walker and Howard Brown provided affirming, comprehensive care that built trust and encouraged vaccination and early treatment. As mpox reemerges globally, their role remains essential. Yet these centers now face devastating funding threats amid proposals to slash federal support. Safeguarding LGBTQ+ health means sustaining these clinics, investing in tailored care, and confronting stigma—not turning away. Community health centers save lives and should be fortified, not defunded.

Mpox Vaccine Manufacturer Urged to Drop Price Amid Huge Shortfall in Africa

June 13, 2025

Africa is facing a dire mpox vaccine shortfall, with only half of the 6.4 million needed doses funded, warns Africa CDC’s Dr. Ngashi Ngongo. Countries hardest hit—Sierra Leone, Uganda, and the DRC—are struggling as vaccine deliveries fall far short of requests. High prices, especially the $65-per-dose MVA-BN vaccine from Bavarian Nordic, are straining budgets and hindering rollout. UNICEF, also facing a steep income drop, cannot afford the 350,000 remaining doses in its current deal. With U.S. funding sharply cut and testing rates declining in the DRC, urgent global support is needed to avoid a deeper public health crisis.

West Africa: As Mpox cases surge, health workers struggle to keep up

June 12, 2025

The surge in mpox cases in Sierra Leone and Liberia is straining fragile health systems and placing frontline workers at critical risk amid global vaccine shortages. With Sierra Leone reporting over 3,900 infections and Liberia 870 suspected cases, health workers are stretched thin and often unprotected. CARE and national public health agencies are implementing infection control and risk communication, but limited vaccine access threatens containment. This outbreak, driven by a new strain, underscores the urgent need for sustained investment in vaccines and community engagement. Delayed action risks deeper transmission across Africa and beyond—time and resources are running out.

Mpox: updates from the WHO European Region

June 12, 2025

Mpox remains a persistent threat in the WHO European Region, with over 200 cases reported monthly—mostly Clade II infections among men who have sex with men. Although the initial Public Health Emergency of International Concern (PHEIC) was lifted in 2023, the resurgence of Clade Ib in the Democratic Republic of the Congo and its spread in 2024 prompted the WHO to declare a second PHEIC. On 12 June, WHO/Europe will convene Member States to assess surveillance, control, and elimination strategies. This webinar is a timely call to enhance regional preparedness and ensure sustained momentum against a still-active global health threat.

As mpox escalates in Sierra Leone, activity in other countries reflects mixed picture

June 12, 2025

Mpox cases in Africa present a varied landscape—some countries like the DRC and Uganda are seeing declines, while others, including newly affected nations such as Sierra Leone, Liberia, Ghana, and Malawi, face surging infections. Sierra Leone alone accounted for 63% of all confirmed mpox cases in Africa last week. Africa CDC and WHO have extended their respective emergency declarations as vaccine shortages and low testing coverage hamper containment. A shipment of 97,600 vaccine doses is expected mid-June, but challenges with contact tracing and equitable vaccine allocation continue to threaten response effectiveness. Ring vaccination remains critical to stopping further spread.

Sierra Leone Is Battling an Mpox Outbreak. What Happens Next Affects Us All

June 11, 2025

Sierra Leone is at the epicenter of a fast-moving and deadly mpox outbreak. A newly identified variant, G.1, is spreading rapidly, doubling every two weeks, with genomic data suggesting over 11,000 infections. Local teams are responding with remarkable speed—sequencing, tracing, and deploying real-time tracking tools like Lookout and Sentinel. But their resources are drying up. U.S. funding cuts and global vaccine scarcity are compounding risk. The world must act now: this outbreak is no longer localized, with G.1 cases already appearing in the U.S. and Europe. Sierra Leone cannot and should not face this epidemic alone.

Mpox Vaccine Shortfall - Jynneos (MVA-BN) Still Priced at a Premium

June 9, 2025

As Africa’s mpox outbreak escalates, vaccine supply remains dangerously inadequate. On June 5, 2025, Africa CDC’s Dr. Ngashi Ngongo flagged Bavarian Nordic’s high price for MVA-BN (Jynneos) as a key barrier. Despite 1.3 million doses allocated, over 6 million are still needed. UNICEF lacks funding to procure its remaining doses, and U.S.-pledged supplies face delays due to past administrative disruptions. With cases soaring in countries like Sierra Leone and DRC, continued supply scarcity—driven by unaffordable pricing—jeopardizes outbreak control. Bavarian Nordic must urgently lower MVA-BN’s price and enable technology transfer to ensure equitable access and protect global health.

Mpox epidemic remains international health emergency warns WHO

June 9, 2025

On June 5, 2025, WHO Director-General Dr. Tedros Adhanom Ghebreyesus reaffirmed mpox as a Public Health Emergency of International Concern, following the International Health Regulations Emergency Committee meeting. With over 37,000 confirmed cases and 125 deaths across 25 countries since early 2024, the epidemic remains deeply entrenched. The Democratic Republic of the Congo accounts for 60% of cases, while Uganda, Burundi, and Sierra Leone face mounting surges. Despite some progress, the resurgence in West Africa and undetected spread globally demand urgent international coordination, improved surveillance, and funding to prevent further escalation of this complex, transcontinental public health threat.

Analysis shows mpox lurked in Nigeria for 8 years before igniting global 2022 outbreak

June 6, 2025

A groundbreaking gene-tracking study published in Nature confirms that clade 2 mpox circulated in Nigeria undetected for eight years before triggering the 2022 global outbreak. Researchers estimate the virus first infected humans in southern Nigeria in 2014 and spread silently due to poor surveillance. Of 118 genomes analyzed, nearly all Nigerian cases showed sustained human-to-human transmission, while Cameroon cases reflected animal spillover. Lead author Edyth Parker stressed that limited access to vaccines, diagnostics, and surveillance tools in Africa facilitated the unchecked spread. The findings are a stark reminder: neglecting local epidemics endangers global health.

Sierra Leone battles intense mpox activity as Ethiopia reports first death

June 6, 2025

Mpox activity in Africa is escalating rapidly, with new surges in Sierra Leone and Ethiopia raising alarm. At a recent Africa CDC briefing, Dr. Ngashi Ngongo confirmed nearly 17,845 lab-confirmed cases by May—approaching 2024’s full-year total. Sierra Leone alone accounted for 53% of last week’s cases, and Ethiopia reported its first mpox-related death, an infant. Passive surveillance, high-density populations, and complex transmission dynamics are fueling the spread. Emergency declarations by Africa CDC and WHO remain under review. With new vaccine shipments arriving in the DRC, Sierra Leone, and Ethiopia, equitable distribution and intensified response remain critical for containment.

11 patients with confirmed, suspected mpox are HIV-positive

June 6, 2025

A recent cluster of mpox cases at the Southern Philippines Medical Center revealed a concerning overlap: 11 of 14 patients also tested positive for HIV. The majority were male, with no significant travel history, and transmissions likely occurred through close or sexual contact. While health authorities urge caution, they clarified that mpox is not airborne, and lockdowns are unnecessary. Facemask use is recommended in crowded spaces but not mandatory. With mpox declared a global public health emergency in 2024 and HIV infections in the Philippines surging, officials are calling for vigilance, testing, and community education on both diseases’ overlapping risks.

WHO Director-General's opening remarks at the IHR Emergency Committee meeting regarding the upsurge of mpox 2024 – 5 June 2025

June 5, 2025

In his opening remarks at the 5 June 2025 IHR Emergency Committee meeting, WHO Director-General Dr. Tedros Adhanom Ghebreyesus addressed the alarming mpox upsurge, citing over 37,000 confirmed cases and 125 deaths globally in 2024. The Democratic Republic of the Congo alone accounts for 60% of confirmed cases. Despite the deployment of 2.9 million vaccine doses across 13 countries, only 724,000 have been administered. Dr. Tedros called for urgent funding—$147 million—to sustain surveillance, response, and vaccination efforts. Amid rising transmission and widening geographic spread, he emphasized the critical need for cross-border coordination, local engagement, and sustained international commitment.

Mpox Research Is Helping Scientists Prepare for a New Pandemic

June 4, 2025

The 2022 global mpox outbreak, which struck the U.S. with over 20,000 cases, led to widespread use of tecovirimat (TPOXX) under emergency protocols. A major clinical trial led by UC San Francisco has now confirmed that while TPOXX was safe, it did not accelerate recovery. This mirrors findings from a parallel trial in the Democratic Republic of the Congo. The trial's inclusive design—incorporating pregnant women and children—underscores the ethical imperative of equitable research. As mpox remains a WHO-declared public health emergency, these findings emphasize the need for more robust antiviral strategies and continued investment in outbreak-responsive clinical trials.

Q&A: How mpox research is helping scientists prepare for a new pandemic

June 4, 2025

The mpox outbreak of 2022 devastated communities across the U.S., including San Francisco. Yet the widely used antiviral TPOXX failed to speed recovery in clinical trials led by UC San Francisco and the Democratic Republic of the Congo. While the drug was safe, results showed no significant benefit—underscoring the urgency of developing more effective therapeutics. The inclusion of pregnant women and children in open-label study arms marked an ethical advancement in clinical trial design. This experience demonstrates why real-time, equitable trials are essential during health emergencies to ensure that treatment strategies are both evidence-based and inclusive from the outset.

African countries fall far short of mpox vaccination targets

June 4, 2025

Africa’s escalating mpox crisis has been met with an underwhelming global vaccination response, jeopardizing containment efforts. Despite an initial goal to vaccinate 10 million people, only 720,000 have received vaccines across the continent, with supply shortfalls and logistical hurdles delaying rollout. In conflict-ridden hotspots like the Democratic Republic of the Congo, fragile health systems have buckled under rising cases. Africa CDC’s ring vaccination strategy has stalled, hindered by limited lab access and resource constraints. With global equity in question and manufacturers reluctant to share technology, African nations are left to stretch scant doses. Bold investments and regional production are urgently needed.

DOH 7 heightens alert for Mpox

June 3, 2025

The Department of Health Central Visayas Center for Health Development (DOH Central Visayas CHD) in the Philippines has issued a strong call for vigilance as mpox cases reemerge in the region. Highlighting the virus’s transmission through intimate contact and contaminated materials, authorities stress the importance of hygiene, respiratory etiquette, and early detection. Regional Director Joshua Brillantes urged compassion, accurate information, and community cooperation over fear and stigma. With enhanced surveillance now in place, residents are reminded to seek immediate medical care if symptoms appear and avoid misinformation. Public health remains a shared responsibility, and Central Visayas is prepared to respond with vigilance and transparency.

Spike in Mpox Cases

June 2, 2025

Liberia’s confirmation of 69 active mpox cases is a stark reminder that the region remains vulnerable to infectious disease threats. While the country has reported zero deaths, the circulation of both Clade IIa and IIb strains, coupled with regional mobility, poses a significant risk. The National Public Health Institute of Liberia (NPHIL) is acting swiftly, issuing a national health advisory and encouraging hygiene, surveillance, and institutional preparedness. As past outbreaks have shown, community engagement is critical. Continued vigilance, cross-border coordination, and public compliance are essential to prevent further spread and protect Liberia’s growing but still fragile health infrastructure.

Explosive mpox outbreak in Sierra Leone overwhelms health systems

June 2, 2025

Sierra Leone’s explosive mpox outbreak, now accounting for three-quarters of all new African cases, underscores an urgent need for expanded vaccine access and global attention. With limited bed capacity and only 61,000 vaccine doses received so far, the country is ill-equipped to manage a fast-spreading crisis. Scientists are puzzled by Clade IIb’s behavior, which mimics the more severe Clade Ib strain in transmission and symptoms. While sexual contact appears to be the primary driver, concerns linger about other transmission modes. Immediate vaccine deployment and international support are essential to avert regional spillover and prevent a broader global resurgence.

U.S. CDC issues alert as mpox outbreak in Central, East Africa leads to new cases in the U.S.

May 31, 2025

The CDC’s recent health alert underscores the seriousness of the Clade I mpox outbreak in Central Africa, particularly the Democratic Republic of the Congo. Although no sustained U.S. transmission has occurred, travel-linked cases signal a need for vigilance. Clade I is more severe than its Clade II counterpart and has caused fatalities abroad. Healthcare providers must be proactive—screening travelers, reporting suspected cases, and encouraging vaccination. The JYNNEOS vaccine remains protective against both clades. Now is not the time for complacency. Early detection and vaccination outreach are key to preventing a domestic resurgence of a more dangerous strain.

Twelve African Nations to Boost Cross-Border Efforts Against Mpox, Health Crises

May 31, 2025

The mpox outbreak in Africa underscores the urgent need for cross-border coordination. With over 16,000 confirmed cases and more than 1,180 deaths, 12 African nations have committed to a unified response framework. This agreement—facilitated by the World Bank, Africa CDC, WHO, and partners—will improve surveillance, streamline data sharing, and address transmission challenges across borders. Epidemics respect no borders; thus, regional cooperation is critical. By aligning resources and strengthening governance, Africa is taking a proactive stance in disease containment, resilience building, and equitable health access. It’s a blueprint for managing not only mpox but all future health emergencies.

Sierra Leone seeks help for growing mpox outbreak

May 31, 2025

Sierra Leone’s escalating mpox crisis—with over 3,300 cases and 16 deaths since January—underscores the urgent need for international support. Despite opening a 400-bed treatment center and vaccinating over 42,000 frontline workers, the country is struggling to keep pace. Deputy Health Minister Charles Senessie’s appeal for global assistance must be met with swift action. Mpox remains a public health emergency across Africa, and Sierra Leone’s containment efforts are vital not just locally, but regionally. Global solidarity, including vaccine donations and logistical support, is essential to prevent further spread and strengthen the nation’s strained health infrastructure.

Oregon health Q&A: What is the latest with mpox in Oregon?

May 31, 2025

As Oregon enters Pride season, it's encouraging that mpox cases remain low—just eight reported in 2025. Yet the virus has not disappeared. With intimate skin-to-skin contact remaining the primary mode of transmission, continued caution and vaccination are vital. Oregon Health Authority rightly urges those at risk to complete their two-dose vaccine series, which offers up to 80% protection. Summer festivities should not ignore public health. Ensuring access to mpox vaccines, especially for LGBTQ+ communities, is a proactive step toward safe celebration. Staying informed and vaccinated protects both individuals and the broader community.

Health authorities stress prevention as LGUs detect Mpox

May 29, 2025

The detection of mpox cases in South Cotabato and Iloilo has triggered swift action by local governments in the Philippines, reflecting a commendable emphasis on prevention. From mandatory masking among health personnel in Polomolok and Cagayan de Oro to enhanced isolation protocols in Iloilo, LGUs are proactively reinforcing public health measures. With rising community cases and no history of travel among patients, vigilance must remain high. Public compliance—especially through masking, hand hygiene, and early symptom reporting—is crucial. As we learned from COVID-19, early intervention and widespread community engagement are key to curbing outbreaks before they escalate.

Africa CDC Appeals for More Mpox Vaccines, as Ethiopia Reports first cases

May 29, 2025

Africa urgently needs 6.4 million mpox vaccines to contain a rapidly escalating outbreak centered in Sierra Leone, which now accounts for three-quarters of the continent's confirmed cases. With just 10,000 doses available in-country and cases reported in 19 nations—including Ethiopia’s first three—there is a critical shortfall. Africa CDC has appealed for global solidarity as new cases rise sharply, nearly matching 2024's total in just five months. Japan’s pledged 1.5 million LC16 vaccines are expected imminently, but sustained funding and strategic allocation are essential to prevent further regional spread and blunt the compounded impact of concurrent disease outbreaks.